Trial · NCT04154826
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease
NCT04154826, Phase 2, Terminated, Revimmune
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease. Trials, record NCT04154826. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04154826
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease
- NCT number
- NCT04154826
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Revimmune
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- Recombinant human interleukin-7
- First posted
- 2019-11-07
- Last updated
- 2024-04-11
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determination of the proportion of subjects with Acid Fast Bacilli (AFB) sputum culture conversion to negative at day 180. | six months | Percentage of participants with 3 consecutive monthly, negative Acid Fast Bacilli sputum cultures at any time within first 6 months |
| Secondary | Efficacy by kinetic of AFB sputum culture conversion to negative. | one year | number of patients with negative sputum conversion measured at days 28, 56, 84, 112, 140, 180, 240, 300, and 360. |
| Secondary | Improvement of functional capacity response assessed by the median change in the 6-minute walk distance compared to baseline. | one year | Increase in 6-minute walking distance measured at days 84, 180 and 360 over baseline distance |
| Secondary | Improvement of functional capacity response assessed by the median change in oxygen saturation compared to baseline. | one year | Increase in oxygen saturation measured at days 84, 180 and 360 over baseline value |
| Secondary | Pulmonary function response measured by the median improvement in the Forced expiratory volume during the first second (FEV1). | one year | ratio of Forced Expiratory Volume during the first second (FEV1) measured at days 180 and 360 over the same measure at baseline. |
| Secondary | Radiological response on chest CT compared to baseline | one year | Surface area of lung involved by clinical chest computerized tomography (CT) scans at days 180 and 360 compared to baseline |
| Secondary | Improvement of Health-related Quality of Life (HRQoL) | one year | Patient-Reported Outcomes Measurement Information System (PROMIS-29 ) measured at days 56, 84, 180, 300 and 360 and compared to baseline. (The mean healthy population score is 50. The score increases with worsening medical condition.) |
| Secondary | Number of hospital readmissions | one year | Cumulated Number of hospital (Intensive care unit or emergency room ) visits at days 56, 84, 180, 300 and 360 |
| Secondary | C max (maximal plasma concentration) pharmacokinetic of CYT107 in this population | One day | At Day 1 and Day 78 measure of CYT107 Cmax |
| Secondary | Plasma concentration area under curve (AUC) pharmacokinetic of CYT107 in this population | One day | At Day 1 and Day 78 measure of CYT107 AUC |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40351870 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04154826
GET https://conductscience.org/api/trials/v1/NCT04154826/registered